JP2007531728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007531728A5 JP2007531728A5 JP2007506303A JP2007506303A JP2007531728A5 JP 2007531728 A5 JP2007531728 A5 JP 2007531728A5 JP 2007506303 A JP2007506303 A JP 2007506303A JP 2007506303 A JP2007506303 A JP 2007506303A JP 2007531728 A5 JP2007531728 A5 JP 2007531728A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- antibody
- binds
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 26
- 239000003112 inhibitor Substances 0.000 claims 14
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 13
- 108010022394 Threonine synthase Proteins 0.000 claims 12
- 102000005497 Thymidylate Synthase Human genes 0.000 claims 12
- 229960002949 fluorouracil Drugs 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 9
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 8
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 claims 6
- 239000003102 growth factor Substances 0.000 claims 6
- 230000009870 specific binding Effects 0.000 claims 6
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 229960004117 capecitabine Drugs 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 4
- 229960000397 bevacizumab Drugs 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 239000000890 drug combination Substances 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- MMBZCFJKAQZVNI-VPENINKCSA-N 4-amino-5,6-difluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound FC1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 MMBZCFJKAQZVNI-VPENINKCSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 229940120638 avastin Drugs 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229950006410 tezacitabine Drugs 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- UEJQGOKMPMUMTO-UHFFFAOYSA-N C(C#C)OC1=NC=C(C(=N1)OCC#C)F Chemical compound C(C#C)OC1=NC=C(C(=N1)OCC#C)F UEJQGOKMPMUMTO-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55888904P | 2004-04-02 | 2004-04-02 | |
| US62547904P | 2004-11-04 | 2004-11-04 | |
| US65874505P | 2005-03-04 | 2005-03-04 | |
| PCT/US2005/011046 WO2005097086A2 (en) | 2004-04-02 | 2005-04-01 | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007531728A JP2007531728A (ja) | 2007-11-08 |
| JP2007531728A5 true JP2007531728A5 (enExample) | 2008-05-01 |
Family
ID=35125596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506303A Pending JP2007531728A (ja) | 2004-04-02 | 2005-04-01 | 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070280944A1 (enExample) |
| EP (1) | EP1740182A2 (enExample) |
| JP (1) | JP2007531728A (enExample) |
| AU (1) | AU2005231436A1 (enExample) |
| CA (1) | CA2561952A1 (enExample) |
| IL (1) | IL178261A0 (enExample) |
| WO (1) | WO2005097086A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871279B2 (en) * | 2000-03-09 | 2014-10-28 | Yale University | Use of the combination of PHY906 and a tyrosine kinase inhibitor as a cancer treatment regimen |
| US8372834B2 (en) | 2007-03-02 | 2013-02-12 | University Of Wollongong | Compositions and methods for delivery of anti-cancer agents |
| WO2008109349A1 (en) * | 2007-03-06 | 2008-09-12 | Adventrx Pharmaceuticals, Inc. | Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine |
| JP2012503640A (ja) * | 2008-09-26 | 2012-02-09 | センター リージョナル ド ルッタ コントレ ル キャンサー ダンジェ | Ｆｏｌｆｉｒｉ治療における５−フルオロウラシル用量の個別最適化方法 |
| WO2010035075A1 (en) * | 2008-09-26 | 2010-04-01 | Centre Regional De Lutte Contre Le Cancer D'angers | Individual 5-fluorouracile dose optimization in folfox treatment |
| EP2617422A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate |
| EP2617421A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer |
| WO2018065446A1 (en) * | 2016-10-05 | 2018-04-12 | Isofol Medical Ab | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| EP3446704A1 (en) * | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| EP3446703A1 (en) * | 2017-08-24 | 2019-02-27 | Isofol Medical AB | 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
| WO2018065445A1 (en) * | 2016-10-05 | 2018-04-12 | Isofol Medical Ab | [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
| EP3305318A1 (en) * | 2016-10-05 | 2018-04-11 | Isofol Medical AB | [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy |
| KR20190112711A (ko) * | 2017-02-14 | 2019-10-07 | 이소폴 메디컬 에이비 | 혈장 2'-데옥시우리딘 (dUrd) 및 티미딜레이트 신타제 억제를 증가시키는 방법 |
| KR20200107988A (ko) * | 2018-01-05 | 2020-09-16 | 이소폴 메디컬 에이비 | 결장직장암 및 전이성 결장직장암의 치료 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376658A (en) * | 1990-05-11 | 1994-12-27 | University Of Southern California | 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent |
| US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
-
2005
- 2005-04-01 CA CA002561952A patent/CA2561952A1/en not_active Abandoned
- 2005-04-01 AU AU2005231436A patent/AU2005231436A1/en not_active Abandoned
- 2005-04-01 JP JP2007506303A patent/JP2007531728A/ja active Pending
- 2005-04-01 US US10/594,850 patent/US20070280944A1/en not_active Abandoned
- 2005-04-01 EP EP05732160A patent/EP1740182A2/en not_active Withdrawn
- 2005-04-01 WO PCT/US2005/011046 patent/WO2005097086A2/en not_active Ceased
-
2006
- 2006-09-21 IL IL178261A patent/IL178261A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007531728A5 (enExample) | ||
| ES2338109T3 (es) | Producto de combinacion de inhibidor de la familia src de las tirosina quinasas no receptoras y gemcitabina para uso en el tratamiento o profilaxa de cancer de pancreas. | |
| JP2010520289A5 (enExample) | ||
| JP2020512314A5 (enExample) | ||
| JP5551589B2 (ja) | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 | |
| CN1703223A (zh) | 喹唑啉衍生物 z d 6 4 7 4组合吉西他滨并任选组合电离辐射在治疗与血管生成和 /或血管通透性增加相关的疾病中的用途 | |
| JP2008530248A5 (enExample) | ||
| RU2010151602A (ru) | Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства | |
| JP2011520921A5 (enExample) | ||
| CN1674908A (zh) | erb B激酶抑制剂和抗肿瘤疗法的联合治疗 | |
| CN112236147A (zh) | 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法 | |
| WO2017184086A1 (en) | Method of treating liver cancer | |
| JP2007277240A5 (enExample) | ||
| JP2007531728A (ja) | 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用 | |
| CN1658880A (zh) | 用于治疗癌症的联合疗法 | |
| EP2139469A2 (en) | Cobalamin taxane bioconjugates | |
| JP6174044B2 (ja) | Ｅｇｆｒ阻害剤と組み合わせたテトラヒドロフォレート | |
| CA3098204A1 (en) | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof | |
| Moehler et al. | New chemotherapeutic strategies in colorectal cancer | |
| CN114173785B (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| CN101355969B (zh) | 包含cyc-682和细胞毒性药物的抗增殖性组合 | |
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| JP2014034531A (ja) | Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ | |
| Choi et al. | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer | |
| JPWO2021022256A5 (enExample) |